Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2

Article Microbiology

Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets

Robert M. Cox et al.

Summary: Treating SARS-CoV-2-infected ferrets with nucleoside analogue MK-4482/EIDD-2801 reduced viral load and suppressed virus spread. This therapeutic approach shows promise in breaking transmission chains of the COVID-19 pandemic.

NATURE MICROBIOLOGY (2021)

Add to Collection

Article Microbiology

AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19

Steven S. Good et al.

Summary: AT-527, an oral antiviral drug, has potent activity against various coronaviruses, including SARS-CoV-2. In vitro experiments have shown that AT-511 has high efficacy in inhibiting the replication of SARS-CoV-2, with minimal cytotoxicity. Studies suggest that AT-527 may be an effective treatment option for COVID-19.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Potency and pharmacokinetics of GS-441524 derivatives against SARS-CoV-2

Daibao Wei et al.

Summary: Nucleoside metabolite GS-441524, an analog of remdesivir, shows potent anti-SARS-CoV-2 efficacy but has poor oral bioavailability in non-human primates. Various GS-441524 analogs with modifications and prodrug forms were developed, with the 7-fluoro analog 3c and certain prodrugs demonstrating moderate to excellent activities and oral bioavailabilities, providing insights for pharmacokinetic optimization.

BIOORGANIC & MEDICINAL CHEMISTRY (2021)

Add to Collection

Article Medicine, General & Internal

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Roujian Lu et al.

LANCET (2020)

Add to Collection

Article Medicine, General & Internal

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Yeming Wang et al.

LANCET (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment

Jing Sun et al.

CELL (2020)

Add to Collection

Article Chemistry, Medicinal

Derivatives of imidazotriazine and pyrrolotriazine C-nucleosides as potential new anti-HCV agents

Alistair G. Draffan et al.

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2014)

Add to Collection

Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2

Related references

Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets

AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19

Potency and pharmacokinetics of GS-441524 derivatives against SARS-CoV-2

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment

Derivatives of imidazotriazine and pyrrolotriazine C-nucleosides as potential new anti-HCV agents

Export Citation

Share Paper